Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.
Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.
| Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|---|
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
| India | U.S. |
Centhaquine (Lyfaquin®) is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock...
Read More
Septic shock is defined as a life-threatening organ dysfunction caused by a dysregulated host response to ...
Read More
Acute kidney injury (AKI) is a common complication in critically ill patients and is associated with increased...
Read MoreThe management team is well balanced with significant drug development and clinical expertise, and commercialization experience. In addition to the management and development team in the US, the company has over 80 employees through its subsidiary in India.
More Details
Dr. Gulati is leading clinical development and commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock.
Dr. McDonnell received his undergraduate degree from Georgetown University and his MD in 1985 from Northwestern University. Dr. McDonnell has also received postgraduate training in Emergency and Internal Medicine at Northwestern University.
By EP News Bureau On Aug 2, 2023 -- Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary..
By BioSpectrum India On Aug 2, 2023 -- Pharmazz India, a majority-owned subsidiary of US-based Pharmazz, Inc. s first-in-class
By Pharmabiz On Aug 2, 2023 -- Pharmazz India Private Limited, a majority-owned subsidiary of Pharmazz, Inc, has announced
